Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NWRD18
- Development stage
- Phase 1
- Lead developer
- Novet Bio-Tech
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
NWRD18 is an orally bioavailable, highly selective small molecule inhibitor of the MDM2-p53 interaction, developed by Novet Bio-Tech. It is designed to treat cancers characterized by MDM2 amplification or overexpression, such as certain types of soft tissue sarcoma. By blocking the binding of MDM2 to the p53 tumor suppressor protein, NWRD18 prevents p53 degradation, thereby restoring its ability to induce cell cycle arrest and apoptosis in malignant cells. The drug is currently undergoing Phase I clinical evaluation in China for patients with advanced, unresectable, or metastatic soft tissue sarcoma who have progressed on standard therapies.
02
Targets
MDM2 (Mouse double minute 2 homolog)
Beyond the preview
Go deeper on NWRD18.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NWRD18.